Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens.

Blood cancer journal - 30 Jun 2017

Lopes-Aguiar L, Delamain M T, Brito A B C, Lourenço G J, Costa E F D, Oliveira G B, Vassallo J, De Souza C A, Lima C S P

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to Glutathione Transferase
Share to Multiple Myeloma
Share to Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Survival Rate

Share to Thalidomide

Share to Vascular Endothelial Growth Factor A

Share to Vascular Endothelial Growth Factor Receptor-2

Source

Open in PubMed Open full text

Identifiers

PMID: 28665417
DOI: 10.1038/bcj.2017.58
PMCID: PMC5520405

Genes

GSTM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens.PMID 28665417Read ↗

Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.Semantic proximity Read ↗

Polymorphisms of glutathione S-transferase mu1 (GSTM1) and theta1 (GSTT1) genes in multiple myeloma.Semantic proximity Read ↗

MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma.Semantic proximity Read ↗

Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma.Semantic proximity Read ↗

Deciding on the therapy of multiple myeloma using genetic risk stratification.Semantic proximity Read ↗

MDR1 polymorphisms affect the outcome of Chinese multiple myeloma patients.Semantic proximity Read ↗

Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients.Semantic proximity Read ↗

Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide.Semantic proximity Read ↗

Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.Semantic proximity Read ↗

Genetic mutations and outcome in myeloma.Semantic proximity Read ↗

Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma.Semantic proximity Read ↗

MDR1 diplotypes as prognostic markers in multiple myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.